Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 19/20 | 0.44 |
| ▸ | IRAK1 | P51617 | 3/20 | 0.40 |
| ▸ | CLK1 | P49759 | 2/20 | 0.40 |
| ▸ | CLK2 | P49760 | 2/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.40 |
| ▸ | IRAK3 | Q9Y616 | 2/20 | 0.40 |
| ▸ | IRAK2 | O43187 | 1/20 | 0.40 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
| ▸ | CCNC | P24863 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
| ▸ | CDK7 | P50613 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
| ▸ | CCNH | P51946 | 1/20 | 0.39 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.39 |
| ▸ | ADK | P55263 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21997957 | 0.88 | ADK (0.36) | IRAK4IRAK1CLK1CLK2CLK4 | |
| SCHEMBL23807580 | 0.85 | IRAK4 (0.54) | IRAK4IRAK1CLK1CLK2CLK4 | |
| SCHEMBL23788164 | 0.85 | IRAK4 (0.54) | IRAK4IRAK1CLK1CLK2CLK4 | |
| SCHEMBL21069846 | 0.80 | BTK (0.42) | IRAK4IRAK1CLK1CLK2CLK4 | |
| SCHEMBL21070447 | 0.78 | IRAK4 (0.41) | IRAK4IRAK1CLK1CLK2CLK4 | |
| SCHEMBL21106432 | 0.78 | IRAK4 (0.41) | IRAK4IRAK1CLK1CLK2CLK4 | |
| SCHEMBL23807679 | 0.73 | IRAK4 (0.48) | IRAK4IRAK1CLK1CLK2CLK4 | |
| SCHEMBL21997482 | 0.73 | IRAK4 (0.48) | IRAK4IRAK1CLK1CLK2CLK4 | |
| SCHEMBL21996968 | 0.72 | IRAK4 (0.48) | IRAK4IRAK1CLK1CLK2CLK4 | |
| SCHEMBL26796791 | 0.72 | IRAK4 (0.48) | IRAK4IRAK1CLK1CLK2CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
| EP-3886904-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| WO-2020113233-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | IRAK4 4/4885IRAK1 3/4885CLK1 2294/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | IRAK4 4/4885IRAK1 3/4885CLK1 2294/4885 |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | IRAK4 4/4885IRAK1 3/4885CLK1 2294/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | IRAK4 4/4885IRAK1 3/4885CLK1 2294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.